Montelukast Medreg

Montelukast, the active ingredient in Montelukast Medreg, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children. It is commonly incorporated into long‑term management plans to reduce symptom frequency and improve quality of life.

GNH USA supplies Montelukast Medreg as a licensed, GDP‑compliant international pharmaceutical supplier, adhering to EU quality standards and providing the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels globally.

Montelukast is a leukotriene receptor antagonist used to manage conditions driven by leukotriene‑mediated inflammation.

Asthma: improves control of persistent asthma and reduces exacerbations. Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea

Serious or Rare Side Effects: - Allergic reactions such as rash, urticaria or angioedema - Neuropsychiatric events including agitation, depression or suicidal thoughts - Angioedema affecting the face, lips or throat - Stevens‑Johnson syndrome or other severe skin reactions

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.

Assess hepatic function: monitor liver enzymes in patients with liver disease. Monitor neuropsychiatric symptoms: watch for mood changes, depression or suicidal ideation. Avoid in known hypersensitivity: discontinue if rash, urticaria or angioedema occurs. Use caution during pregnancy: limited data, weigh benefits versus potential risks. Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Montelukast can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Phenobarbital: enzyme induction reduces Montelukast plasma levels. - Rifampin: strong inducer of hepatic metabolism, decreasing exposure. - Ketoconazole: CYP3A4 inhibition may increase Montelukast concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation. - Beta‑agonists: additive bronchodilatory effect may enhance symptom control. - ACE inhibitors: rare reports of bronchospasm, observe respiratory status.